Diabetes and Metabolic Dysfunction–Associated Steatotic Liver Disease
June 10, 2024 / Type 2 Diabetes / MASLD / Insulin Resistance/ Obesity-related Liver Disease
Type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) share risk factors like obesity and insulin resistance. Managing one condition helps control the other through lifestyle changes and medications.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
June 10, 2024 / Retatrutide / Metabolic Dysfunction / MASLD / Liver Fat Reduction / Clinical Trials
Retatrutide, a triple hormone receptor agonist, significantly reduced liver fat in patients with MASLD over 24 weeks. Higher doses showed up to 82.4% reduction, indicating potential for managing metabolic dysfunction-associated liver disease.
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
June 10, 2024 / Trizepatide / MASH Resolution / Fibrosis improvement / GIP & GLP-1 Receptor
Tirzepatide, a GIP and GLP-1 receptor agonist, significantly improved MASH resolution and fibrosis compared to placebo in the phase 2 SYNERGY-NASH trial, also leading to weight loss.
Experimental GLP-1 Med Might Be Breakthrough Against Fatty Liver Disease
June 10, 2024 / Survodutide / Fatty Liver Disease Treatment / GLP-1 Receptor Agonist
The experimental drug survodutide, a dual GLP-1 and glucagon receptor agonist, showed significant improvement in fatty liver disease markers in 83% of patients, potentially offering a new treatment for MASH.
Boehringer and Zealand intensify GLP1-RA MASH race
June 10, 2024 / MASH Treatment / Liver Fibrosis / Clinical Trials
Boehringer Ingelheim and Zealand Pharma’s GLP-1/glucagon receptor dual agonist, survodutide, significantly improved liver fibrosis in MASH patients. In a phase II trial, 52.3% of treated patients showed improvement compared to 25.8% with placebo.
Millions fewer people may need statins, a new study suggests. But guidelines have yet to agree
June 10, 2024 / Cholesterol Management / Cardiovascular Risk / American Heart Association
A new study suggests that updates to the American Heart Association’s risk model could reduce the number of Americans needing statins by up to 40%. Current guidelines, however, remain unchanged pending further recalibration.
Associations of childhood BMI, general and visceral fat mass with metabolite profiles at school-age
June 8, 2024 / Obesity / Metabolic Health
Higher childhood BMI and total body fat are linked to altered serum metabolites, especially amino acids and phospholipids. A specific metabolite profile improves the identification of metabolically unhealthy children, better than BMI alone.
The association of thyroid autoimmunity with ovarian reserve in women with type 1 diabetes with and without polycystic ovary syndrome
June 8, 2024 / Thyroid Autoimmunity / Ovarian Reserve / Type 1 Diabetes / Polycystic Ovary Syndrome
Thyroid autoimmunity (TAI) does not affect ovarian reserve or hormonal profile in women with type 1 diabetes (T1DM), with or without polycystic ovary syndrome (PCOS). Anti-Müllerian hormone (AMH) levels were influenced only by daily insulin dose.
Father’s diet before conception can impact children’s metabolic health, study finds
June 7, 2024 / Anti-Obesity Medicaltion / Weight Control / Metabolic Health / Exercise
Preconception high-fat diet (HFD) in fathers impacts children’s metabolic health, influencing glucose tolerance and gene expression related to obesity. This is mediated by mitochondrial transfer RNA (mt-tRNAs) changes in sperm.
Study finds new therapeutic targets to fight against type 2 diabetes
June 7, 2024 / Type 2 Diabetes / Fasting Glucose Levels / Insulin Resistance
A study identifies new therapeutic targets for type 2 diabetes by elucidating the mechanisms behind elevated fasting glucose levels in insulin-resistant individuals. This advancement can aid in developing novel treatments for diabetes.
Newly Published Study Reveals Effects of Obesity and Metabolic Syndrome on Breast Cancer
June 6, 2024 / Obesity / Breast Cancer / Metabolc Syndrome Effects / Women’s Health
Obesity and metabolic syndrome independently increase breast cancer risk, influencing different subtypes. Managing both conditions is crucial for reducing diagnosis and mortality rates.
Under pressure – the growing problem of insulin resistance
June 6, 2024 / Insulin Resistance / Metabolic Health / Diabetes / Obesity / Cardiovascular-kidney-metabolic Syndrome / Chronic Disease Prevention
Insulin resistance underlies many serious conditions, not just diabetes and obesity. Addressing it can improve overall metabolic health, reducing risks of cardiovascular, kidney, and other diseases.
Certain Liver Histologic Features Predict Long-Term MASH Progression and Outcomes
June 6, 2024 / Liver Histology / MASH Progression / Liver Inflammation
A real-world study indicates that liver histologic features, especially fibrosis stage, predict long-term outcomes in MASLD and MASH patients. Lower fibrosis and liver inflammation correlate with reduced risks of cirrhosis and cardiovascular events.
Metabolic alliance: pharmacotherapy and exercise management of obesity
June 5, 2024 / Anti-obesity medications / Hormones / Weight Control / Metabolic Health / Obesity Treatment
Anti-obesity medications using incretin hormones improve weight control and metabolic health. Exercise complements these treatments, boosting their long-term success and efficacy.
Correlation between newborn weight and serum BCAAs in pregnant women with diabetes
June 5, 2024 / Newborn Weight / Pregnancy Diabetes / Gestational Diabetes
Higher serum BCAA levels in pregnant women with preexisting diabetes correlate with increased newborn weight. This correlation is not observed in women with gestational diabetes or healthy pregnancies.
Saghmos Therapeutics Announces Issuance of U.S. Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
June 5, 2024 / Saghmos Therapeutics / Cardiorenal Metabolic / Kidney Injury Prevetion / Clinical Trials
Saghmos Therapeutics’ Phase 3-ready cardiorenal metabolic modulator, ST-62516, has received a U.S. patent for preventing contrast-induced acute kidney injury and major adverse cardiac and kidney events during procedures like PCI. The patent ensures exclusivity until 2037.
Researchers discover age-related changes in the lipid metabolism of mice
June 4, 2024 / Age-related Lipid Metabolism / Gut Bacteria Lipids / Age-related Diseases
Researchers at RIKEN IMS discovered age-related changes in mouse lipid metabolism, including gut bacteria-derived lipid accumulation and sex differences in kidney lipids. These findings may enhance understanding of chronic age-related diseases.
New study reveals how fat in muscles could increase risk of cardiometabolic disease and unhealthy aging
June 3, 2024 / IMAT / Skeletal Muscle Fat / Cardiometabolic Disease / Insulin Resistance
A new study from the Victor Chang Cardiac Research Institute highlights the risks of intermuscular adipose tissue (IMAT) in skeletal muscles, linking its accumulation to muscle loss, type 2 diabetes, cardiovascular disease, and unhealthy aging.